abstract |
D] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridine-2- (Compound 1) and substantially amorphous N- (5-hydroxy-2,4-di-tert-butyl-phenyl) -4-oxo-1H-quinoline-3-carboxamide A method for the preparation of a pharmaceutical composition comprising the solid dispersion containing the solid dispersion, a method for administration thereof, and a kit for treating, reducing severity, or symptomatic treatment of CFTR-mediated diseases such as cystic fibrosis. |